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INTRODUCTION
Antiphospholipid antibody syndrome (APS), also known 
as Hughes Syndrome, is an autoimmune disorder character-
ized by the presence of antiphospholipid antibodies (aPLs) 
and a hypercoagulability of blood which results in throm-
botic events.1 Diagnosis of definite APS, per the standards set 
forth by the International Congress on Antiphospholipid An-
tibodies, requires both clinical and laboratory corroboration.2 
Clinically, patients must present with one or more episodes 
of arterial, venous, or small vessel thrombosis and/or an ad-
verse obstetric event such as spontaneous abortion. Laboratory 
findings must confirm elevated levels of any one of the follow-
ing aPLs: lupus anticoagulant (LA), anticardiolipin antibody 
(aCL), or anti-β2 glycoprotein-1 antibody.2 This disorder can 
occur in association with systemic lupus erythematosus (SLE) 
or another rheumatic or autoimmune disease, however, ap-
proximately half of patients with APS show no evidence of a 
definable associated disease.3 In the past, these two manifesta-
tions of the disorder have been referred to as secondary and 
primary APS, respectively, but the current preferred termi-
nology is APS with or without associated rheumatic disease.2
The exact cause of APS and recurrent thrombosis is not clear, 
as the presence of aPLs alone is not sufficient for a diagnosis, 
with 1 - 5% of healthy individuals testing positive for aPL an-
tibodies.4 Furthermore, the clinical manifestation of APS tends 
to be heterogeneous as hypercoagulability and thrombosis can 
affect any organ system in the body. However, involvement of 
cerebral large vessels is frequent and, after venous thrombo-
sis, the most common clinical symptoms of this disease tend 
to be transient ischemic attacks (TIAs) and stroke.5 Other neu-
rological manifestations can include chorea, epilepsy, mul-
tiple sclerosis-like lesions, psychiatric disorders such as de-
pression and psychosis, migraine, and cognitive impairment.6
Cognitive abnormalities have been documented in individu-
als with elevated aPLs as well as APS.7,8 Between 2 - 5% of patients 
with APS develop dementia or major neurocognitive impair-
ment, while approximately 35% display mild to moderate cogni-
tive impairment.9,10 The most common cognitive difficulties tend 
to be in the domains of attention, verbal fluency, verbal learn-
ing, executive functioning, and short term memory.11,12 Imaging 
of the brain, when available, often indicates diffuse and focal 
ischemic changes, cortical infarcts, and/or cerebral atrophy.6,13
The present case study outlines a woman with APS 
who developed psychiatric and motor-related issues, 
as well as progressive cognitive impairment, at a rela-
tively young age. She underwent a neuropsychologi-
cal evaluation in 2013 at the request of her neurologist.
CASE REPORT
The patient was a 41-year-old, right-handed, multi-racial 
female. Her educational history was significant for complet-
ing high school and trade school. She was employed un-
til 2010 when she became disabled due to chronic fatigue 
and anxiety. At the time of the neuropsychological evalu-
ation, she was living with her second husband of 2 ½ years. 
The patient’s medical history was significant for APS (diag-
nosed in 1998), chronic fatigue syndrome, multiple prior head 
injuries without loss of consciousness (secondary to physical 
abuse from her first husband) during the late 1990s to early 2000s, 
and a head injury with skull fracture and loss of consciousness 
(LOC; of approximately 24 hours according to records) second-
ary to a motor vehicle accident in 1989. The patient’s psychiatric 
history was significant for depression and psychosis, which re-
portedly began in 2005. Because of her psychosis, she was psy-
chiatrically hospitalized three times, with the most recent time 
being in 2012. She carried the following psychiatric diagnoses: 
Mood Disorder Not Otherwise Specified, Psychotic Disorder 
Not Otherwise Specified, and Dependent Personality Disorder. 
Her mood and psychotic disorders were thought to be the re-
sult of her APS. Family history was significant for a myocardial 
infarct in the patient’s mother. The patient’s medications at the 
time of the neuropsychological evaluation included paroxetine 
hydrochloride 20 mg, sulfamethoxazole and trimethoprim DS 
800 - 160 mg twice daily, benztropine mesylate 1 mg, lamotrig-
ine 50 mg, asenapine 10 mg, and acyclovir 200 mg as needed.
CLINICAL COURSE OF APS
The patient was diagnosed with APS at the age of 27 after her 
second miscarriage. Since that time, the patient has had multiple 
transient ischemic attacks secondary to this syndrome, the most 
recent of which occurred one month prior to the neuropsycho-
logical evaluation. Over the past eight years, the patient has had 
depression associated with psychosis, while over the past three 
years she has had worsening depression and a progressive de-
cline in her motor and cognitive abilities. An MRI of the brain 
was conducted just prior to the neuropsychological evaluation 
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secondary to the patient’s decline in functioning, and medical 
records indicated that the results showed “significant” cortical 
atrophy along with subcortical white matter changes (Figure 
1). This reflected a recent change, as prior neuroimaging stud-
ies (CT from 2010 and MRI from 2008) did not reveal cortical 
atrophy and only showed chronic periventricular white matter 
disease. The patient also underwent a lupus work up, which 
revealed that her antinuclear antibody was positive at 1:640.
Figure 1. MRI of the brain showed “significant” cortical atrophy along 
with subcortical white matter changes. 
CLINICAL PRESENTATION
As a result of the patient’s progressive decline in function-
ing, she was referred for a neuropsychological evaluation. At 
the clinical interview, the patient’s motor problems were re-
ported to have caused reduced mobility in the patient’s limbs 
and eye movements (the latter resulting in visual scanning dif-
ficulties). The patient and her husband indicated that she fre-
quently stumbled and fell when walking, and her gait appeared 
to be unsteady. She reported her cognitive difficulties to be 
widespread, but short-term memory seemed to be the most af-
fected, as she would forget what she was doing mid-task. An 
example provided by the patient’s husband was that the pa-
tient once turned water on to do dishes, turned around to get 
things organized, forgot that she was going to do the dishes, 
and walked away with the water running. He also reported that 
the patient would forget to take her medications and that she 
stopped driving due to concerns about her ability to do so safely.
During the course of the evaluation, the patient demonstrated 
difficulty recalling details of her background and medical his-
tory including when her symptoms began. While she was able 
to comprehend casual interview questions, she required repeti-
tion and elaboration of formal test instructions to comprehend 
them. Her speech was slow in rate, somewhat soft in volume, 
and occasionally mildly disarticulate. Thought processes were 
slow but generally logical and coherent. However, persevera-
tion was noted at times during the testing session. There was no 
evidence of delusions or hallucinations, but the patient noted 
that she recently had been experiencing some degree of para-
noia. Affect was somewhat dysphoric. Mood was described as 
fluctuating based on the weather. Psychomotor retardation was 
evident. Insight into her cognitive functioning was impaired. 
Neuropsychological testing was valid based on the patient’s 
performance on empirically-derived validity tests. Premorbid 
intellectual abilities were estimated objectively to be in the aver-
age range of functioning (estimated IQ = 102; 55th percentile). This 
was calculated by entering the patient’s demographic variables 
(i.e., age, sex, ethnicity, and level of education) and performance 
on a word reading task into an established predictive equation.14 
To measure the patient’s current intellectual functioning, she was 
administered the Wechsler Abbreviated Scale of Intelligence - 
Second Edition, which yielded an Intelligence Quotient of 69 (2nd 
percentile), a significant decline in intellectual functioning of two 
standard deviations and a change from “average” to “deficient.” 
The Repeatable Battery for the Assessment of Neuropsycho-
logical Status was administered to examine a range of current 
neurocognitive functions. This measure is composed of 12 sub-
tests that assess verbal and visual learning and memory, visuo-
spatial abilities, expressive language abilities, mental processing 
speed, and simple attention span. The patient’s performance was 
moderately to severely impaired (< 1st percentile) on all subtests 
with the exception of two: a measure of visuospatial line orien-
tation (mildly impaired, 7th percentile) and a measure of con-
frontation naming (average, 30th percentile). The Brief Visuospa-
tial Memory Test - Revised was administered as an assessment 
of visuospatial learning and memory. Again, the patient’s per-
formance was moderately to severely impaired (< 1st percentile). 
The Delis-Kaplan Executive Functioning System was admin-
istered as a measure of higher-level cognition including sus-
tained attention, set-shifting, inhibition, and mental flexibility. 
Across these tasks the patient’s performance was moderately to 
severely impaired (< 1st percentile). Measures of finger tapping, 
grip strength, and grooved pegboard also were administered to 
assess the patient’s motor control and manual dexterity. Finger 
tapping and grooved pegboard had to be discontinued due to 
psychomotor retardation, spasticity, and poor coordination, 
particularly with the non-dominant (left) hand. Grip strength 
was bilaterally impaired but the non-dominant (left) hand was 
significantly weaker than the dominant (right) hand. Finally, 
brief depression and anxiety screening tests indicated that the 
patient was experiencing moderate levels of both conditions.
DISCUSSION
The incidence of dementia or major neurocognitive disor-
der secondary to APS is rare in the literature, with only a small 
percentage of patients subsequently developing severe cogni-
tive problems.9,10 In the current case, comprehensive neuropsy-
chological data were presented on a relatively young patient 
with APS who was thought to have developed major neuro-
cognitive impairment, in addition to psychiatric and motor-
related symptomology, due to her APS. Neuropsychological 
testing showed essentially global cerebral impairment, result-
ing in significant deficits in intellectual functioning, attention, 
mental processing speed, verbal fluency, visuospatial abil-
ity, learning and memory, executive functioning, and bilateral 
motor functioning. When compared to neurologically healthy 
age-matched individuals, this patient’s scores were consis-
tently at or below the 1st percentile. The only test score that was
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not within an impaired range of functioning was a score from 
a confrontation naming test. However, this test has been criti-
cized as it has been shown to have minimal sensitivity to cog-
nitive dysfunction even in patients with neurodegenerative 
dementia processes.15-17 Overall, it was concluded that neuro-
psychological testing provided strong evidence of a significant 
and essentially global central nervous system abnormality.
Because the patient has a history of head trauma, the pos-
sibility that her symptoms might have resulted from this head 
trauma, instead of APS, should be addressed. The patient’s 
history of head trauma was not a primary contributor for nu-
merous reasons. The patient’s head injury with skull frac-
ture occurred in 1989, her other head injuries (due to physical 
abuse) occurred in the late 1990s to early 2000s, and no addi-
tional head injuries occurred after that date. These head in-
juries were not thought to have resulted in any significant, 
longstanding cognitive difficulties, as the patient continued to 
work successfully as a hairdresser until 2010. Neither she nor 
her husband reported any significant cognitive difficulties un-
til 2010. Furthermore, an MRI of the brain from 2008 and a CT 
of the head in 2010 showed no cortical atrophy and only mild 
chronic periventricular white matter disease. Thus, there was 
no evidence of any significant cognitive or neurologic dys-
function predating 2010, and there was no evidence of signifi-
cant residual cognitive deficits from the prior head trauma.
In 2010, the patient began having more TIAs and her hus-
band noticed increased cognitive, motor, and psychiatric is-
sues. These issues progressed over time and an updated MRI 
of the brain, conducted in 2013, showed “significant” cortical 
atrophy along with subcortical white matter changes (Figure 
1). Given that the onset of the patient’s symptoms correspond-
ed with an increase in TIAs (which are common in APS),5 that 
updated neuroimaging showed cortical atrophy and subcorti-
cal white matter changes (which is not uncommon in APS),6,13 
that the progressing symptoms included increased cognitive, 
psychiatric, and motor abnormalities (all of which are com-
mon in APS),6 and that the patient was relatively young and 
physically healthy outside of her APS-related symptomatol-
ogy, and had no other significant risk factors for early-onset 
dementia, it was concluded that this patient’s dementia very 
likely was due to the progression of her documented APS. 
Due to the degree of cognitive impairment resulting from 
her dementia, a recommendation for supervision and as-
sistance with daily activities, like driving a motor vehicle, 
was proposed.  Additional recommendations included pur-
suing legal counsel to set up surrogate decision-making re-
sponsibilities (e.g., guardianship and conservatorship). 
Unfortunately, the patient’s prognosis was poor given the 
etiology and nature of her documented symptoms. Once de-
mentia occurs, there are no treatments to reverse the cognitive 
impairments. Management of APS typically focuses on con-
trolling other symptoms that are a consequence of the disease 
(e.g., psychiatric disturbances and motor symptoms).18 For 
those patients who experience ongoing episodes of thrombo-
sis, stroke, or transient ischemic attacks, the administration 
of anticoagulants and immunosuppressive drugs usually is 
recommended, although randomized controlled trials inves-
tigating the effectiveness of these drugs are limited.19 Thus, 
evidence to suggest that these medications may prevent or 
delay the development of cognitive dysfunction is lacking. 
At the time of the patient’s neuropsychological evaluation, she 
was not taking any anticoagulant or immunosuppressive drugs, 
nor did she report past prescriptions of these medications. It is 
possible that the outcome of her case could have been different if 
such medications had been prescribed. There is not, however, a 
simple linear relationship between the development of cognitive 
dysfunction and a history of central nervous system complica-
tions in APS.10 For example, in a study among patients with APS, 
three patients under the age of 30 developed dementia without 
a history of cerebrovascular accidents.20 Other researchers also 
have cited examples of patients with APS who displayed chorea 
or mild cognitive impairment, but had no focal lesions on im-
aging.21,22 Due to these findings, it has been suggested that the 
disease mechanism that leads to the development of cognitive 
impairment secondary to APS is more complex and cannot be 
explained solely by the occurrence of repeated cerebrovascular 
events. Other proposed ways through which APS can lead to 
cognitive dysfunction includes the role of aPL antibodies in the 
inhibition of astrocyte proliferation and disruption of vascular 
endothelium.23,24 As a result, it is impossible to say whether this 
patient would have had some degree of cognitive decline if she 
would have been prescribed anticoagulants or immunosup-
pressive drugs prior to her recurrent cerebrovascular events. 
Nonetheless, aggressive preventative treatment should be con-
sidered in APS patients, especially when patients report having 
a history of cerebrovascular events and/or cognitive changes.
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